Skip to content

Author

Wade Thompson

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults With Type 2 Diabetes: A Cohort Study.

OBJECTIVE Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiorenal benefits in individuals with type 2 diabetes, but safety data in older adults remain limited. We evaluated the real-world safety of SGLT2is compared with dipeptidyl peptidase 4 inhibitors (DPP-4is) among individuals aged ≥75 yea...

Hanin Harbi, Michael Nesrallah, G. Carney et al. · 0 citations
Open access Sep 2026

Appropriate glycated haemoglobin testing frequency to monitor patients with type 2 diabetes

Glycated haemoglobin (HbA1c) is used to monitor glycaemic control among patients with type 2 diabetes (T2DM). Glycated haemoglobin represents a 3-month glycaemic average, with the most recent 6 weeks of glycaemia having the greatest influence. Analytical and biological variation introduce imprecision into any single Hb...

Wade Thompson, Tom Perry, Guillaume Grenet et al. · 0 citations
Open access Sep 2026

Integrated Diabetes Care in Canadian Long-Term Care: Insights from Residents and Caregivers

Background: In Ontario, Canada, nearly 40% of older adults living in long-term care (LTC) homes have diabetes. Many are managed to intensive glycemic targets counter to current clinical guidelines, which increases residents’ risks for medication-related harm, hypoglycemia, discomfort, and reduced quality of life. Deint...

Kainat Bashir, Wade Thompson, Alexa Muir et al. · 0 citations
Review Open access Sep 2026

Blood pressure targets for hypertension in people with diabetes mellitus

Objectives This is a protocol for a Cochrane review (intervention). The objectives are as follows: To determine if lower blood pressure (BP) targets (i.e. ≤ 130/85 mmHg), compared with standard BP targets (i.e. ≤ 140 to 160/90 to 100 mmHg) are associated with reduction in mortality and morbidity in people with elevated...

Doreen Y. Larvie, Anshula Ambasta, Ciprian D. Jauca et al. · 0 citations
Review Open access Aug 2026

Beta-Blocker Discontinuation in Heart Failure with Preserved or Improved Ejection Fraction: A Systematic Review.

In HFpEF, beta-blocker discontinuation improved functional capacity and quality-of-life at 2 weeks compared with continuation with no clear effect on cognition, echocardiographic parameters or CV biomarkers, but findings on important long-term clinical outcomes was conflicting.

Wade Thompson, Nima Alaeiilkhchi, Lisa M. McCarthy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.